USD10
ABUS Shares
About Arbutus BiopharmaArbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
USD10
ABUS Shares
About Arbutus BiopharmaArbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 24 at 1:30 PM GMT+0
MARKET CAP
$808.50M
OPEN PRICE
Not enough data
LOW (1Y)
$2.71
HIGH (1Y)
$5.10
LOW (24H)
$4.20
HIGH (24H)
$4.60
VOLUME (24H)
$196.00
3,785,922.92%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $4.29 | |
1 Week | $4.38 | |
1 Month | $4.42 |